GlobeNewswire by notified

Aspo Capital Markets Day 2021: Aspo publishes its focused strategy and new financial targets – aims for growth and higher profitability

Share

Aspo Plc
Inside information
December 1, 2021, at 8:45 a.m.


Aspo Capital Markets Day 2021: Aspo publishes its focused strategy and new financial targets – aims for growth and higher profitability

Aspo holds a Capital Markets Day today, December 1, 2021, starting at 1 p.m. in Helsinki. The group's new strategy, updated long-term financial targets and, in more detail, the current state of Aspo's business operations and prospects will be presented. Aspo will also publish its new sustainability targets for the group and its businesses.

Our new long-term financial targets are:

  • Operating profit of 8 per cent (previously 6%)
  • Net sales growth 5–10% per year (new target)
  • Return on equity over 20%
  • Long-term gearing below 130%

"Aspo creates value by owning and developing businesses in the long term. The improved operating profit margin target is supported by Aspo's business development measures and changes in the business portfolio. In addition to organic growth, the aimed growth is driven by investments in acquisitions and a strategic shift towards a compounder profile. Mergers and acquisitions are a key part of value creation, and the aim is to create growth and income flow through these," says Rolf Jansson, CEO of Aspo.

Sustainability forms an integral part of our acquisition process and ownership agenda. Aspo's businesses aim to be forerunners in sustainability. In order to support our ESG commitments Aspo has defined new ESG targets for the material areas of the group and its business operations. The main target is to reduce emission intensity CO2e (tn) / turnover (t€), by 30% by the year 2025. The current level (2020) is 0.44 and the target level (2025) is 0.30.

Aspo 's dividend policy remains unchanged. Aspo aims for annually increasing dividend payments leaving room for strategic investments. The dividend will be paid in two installments as before.

Focusing of Aspo business portfolio

In line with its strategy, ESL Shipping focuses on handysize and coaster ship class operations with the aim of strengthening their leading role as an industrial partner. The goal is to be a pioneer in technological solutions, sustainability, quality of service and new operating design. The shipping company's new operating profit target is 14% (previously 12%). Telko’s organic growth is accelerated by M&A activities and its new target level for operating profit is 8% (previously 6%). Telko will continue to focus on the value-added product segment. Leipurin aims for better profitability through a separate development program launched to improve and harmonize the company's management system by developing both commercial and supply chain management capabilities. The target for operating profit remains unchanged at 5%. In line with its updated strategy, Leipurin aims to expand the bakery business and strengthen its market position in the food industry. Growth supports the operating profit target.

Strategic options are being assessed for the Kauko business and Vulganus Oy, which is part of Leipurin, and these operations have been defined as non-core businesses for Aspo.

Guidance for 2021 unchanged

Aspo’s operating profit will be approximately EUR 30–36 (19.3) million in 2021. The guidance includes the impact of the impairment of Kauko’s goodwill of EUR 3.4 million.

Following Capital Markets Day and presentation materials

The webcast can be followed live on Aspo's website (www.aspo.com) from 1 p.m. today. Webcast recording and presentation materials (in English) will be available on the website after the event.


ASPO Plc

Rolf Jansson
CEO

Further information:
Rolf Jansson, CEO, tel. +358 400 600 264, rolf.jansson@aspo.com
Keijo Keränen, Group Treasurer, +358 400 955 821, keijo.keranen@aspo.com


Distribution:        
Nasdaq Helsinki
Key media
www.aspo.com

Aspo creates value by owning and developing business operations in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these aiming to be forerunners in sustainability. Aspo supports its businesses profitability and growth with the right capabilities. Aspo Group has businesses in 18 different countries, and it employs a total of approximately 960 professionals.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada26.1.2022 07:00:00 CET | Press release

Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomniaCollaboration with Syneos Health to effectively reach the primary care market in Europe and Canada Allschwil, Switzerland& Morrisville, N.C. – January26, 2022 Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada. Simon Jose, Chief Commercial Officer of Idorsia, commented: “Daridorexant represents a significant advance in the treatment of insomnia, and it is now our

Sharing of Staking Rewards Announcement26.1.2022 07:00:00 CET | Press release

January 26th 2022 CoinShares Digital Securities Limited CoinShares Physical Staked Tezos CoinShares Physical Staked Polkadot Sharing of Staking Rewards CoinShares Digital Securities Limited (the “Issuer”) hereby announces in accordance with Condition 5.3.2 of the Conditions of the CoinShares Digital Securities that Staking Rewards in relation to the class (the “Specified Class”) specified below will be applied by a reduction in the Management Fee applicable to the Specified Class to zero and a positive daily accrual to the Coin Entitlement to the Specified Class provided in the table below . Such reduction to the Management Fee and positive daily accrual to the Coin Entitlement shall apply from the start of trading on January 26th, 2022 until a date to be specified in a further announcement in accordance with Condition 5.3.2. ClassISINManagement FeeStaking Reward (positive daily accrual to Coin Entitlement) CoinShares Physical Staked Tezos GB00BMWB4803 Reduced to 0.0% p.a. 3.00% p.a. C

Aino Health AB (publ): Norberg & Partner Sustainable Group AB (publ) tecknar aktier i Aino Health AB (publ).25.1.2022 19:45:00 CET | Pressemelding

Detta pressmeddelande utgör inte ett offentligt uppköpserbjudande eller annars ett erbjudande om att förvärva aktier. Norberg & Partner Sustainable Group AB (publ)tecknar aktier i Aino Health AB (publ) och utlöser därmed budplikt. Norberg & Partner Sustainable Group AB (publ), org.nr 559268-0663 (”Norberg & Partner”) har idag tecknat 15 384 616 aktier i Aino Health AB (publ), org.nr 559063-5073 (”Aino Health”) till ett pris om 0,65 kronor per aktie. Efter förvärvet äger Norberg & Partner cirka 36,38 procent av aktierna och rösterna i Aino Health. Genom förvärvet utlöses budplikt, vilket innebär att Norberg & Partner är skyldig att offentliggöra ett budpliktsbud avseende resterande aktier i Aino Health inom fyra veckor från förvärvet, alternativt avyttra så många aktier så att aktieinnehavet representerar mindre än tre tiondelar av röstetalet för samtliga aktier i Aino Health. För ytterligare information, se Norberg & Partners hemsida. www.norbergpartner.se/ Kontaktperson: Jyrki Eklund,

Sword Group: 2021 Fourth Quarterly Results | Exceptional Profitability25.1.2022 19:15:00 CET | Press release

2021 Fourth Quarterly Results Consolidated Revenue: €59.7m Consolidated Growth: +31.8% Organic Growth: +21.9% EBITDA Margin: 15.0% RESULTS 4TH QUARTER 2021 Q4 (1) €m 2021 2020 Revenue 59.7 45.3 EBITDA 9.0 7.6 EBITDA Margin 15.0% 13.0% (1) non audited figures Organic growth on a like-for-like basis and at constant exchange rates: +21.9%. YEAR 2021 Consolidated Revenue: €214.6m Organic Growth: +21.5% EBITDA Margin: 13.6% ANALYSIS The Revenue for the Fourth Quarter of 2021 amounts to €59.7m in consolidated terms and to €55.2m without taking into account the acquisition of AiM, added to the perimeter on 1 July 2021. The EBITDA margin for the quarter amounts to 15.0% and organic growth to +21.9%. For 2021, the consolidated revenue amounts to €214.6m with an EBITDA margin of 13.6%. Organic growth for the year amounts to +21.5%. The Group established its 2021 Business Plan based on an organic growth hypothesis of 13%. Sword outperformed in terms of growth while maintaining and even exceeding

Aino Health AB (publ): The board of Aino Health resolves on a directed issue of shares to Norberg & Partner Sustainable Group AB (publ).25.1.2022 19:00:00 CET | Press release

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. The board of Aino Health AB (publ), reg. number 559063-5073 (the “Company”) has today, based on the authorisationfrom the annual general meeting on 24th of May 2021, resolved on a directed issue of 15 384 616 shares with deviation from the shareholders’ pre-emption right.The issue is directed to Norberg & Partner Sustainable Group AB (publ) (”Norberg & Partner”) in order to secure the Company’s long-term financing in a time-and cost-efficient manner and entails an estimated capital injection of approximately SEK 10 million. The subscription price was, after negotiations with the subscriber, determined to SEK 0.65 per new share, which corresponds to the market value as assessed by the board. The reason for the deviation from the shareholders’ pre-emptive right is to secure the Company’s long-term financing in a time- and cost-efficient manner. The new shar

Aino Health AB (publ): Styrelsen i Aino Health AB (publ) beslutar om en riktad nyemission till Norberg & Partner Sustainable Group AB (publ).25.1.2022 19:00:00 CET | Pressemelding

Styrelsen i Aino Health AB (publ), org.nr 559063-5073 (”Bolaget”) har, med stöd av bemyndigandet från årsstämman den 24 maj 2021, idag beslutat att genomföra en riktad nyemission av 15 384616 aktier med avvikelse från aktieägarnas företrädesrätt. Nyemissionen är riktad till Norberg & Partner Sustainable Group AB (publ) (”Norberg & Partner”) i syfte att säkra Bolagets långsiktiga finansiering och medför ett förväntat kapitaltillskott om ca 10 miljoner kronor. Teckningskursen har efter förhandling med teckningsberättigade fastställts till 0,65 kronor per aktie, vilket motsvarar av styrelsen bedömt marknadsvärde. Skälet till avvikelsen från aktieägarnas företrädesrätt är att emissionslikviden ska användas i syfte att på ett snabbt och kostnadseffektivt sätt stärka Bolagets långsiktiga finansiering. Betalning för de nyemitterade aktierna sker genom kontant betalning. Antalet aktier i Bolaget ökar med 15 384 616 aktier, från 26 901 155 aktier till 42 285 771 aktier. Aktiekapitalet i Bolaget

EXTRAORDINARY GENERAL MEETING APPROVES INCREASE OF CONDITIONAL CAPITAL AND SIKA PROPOSES ELECTION OF GORDANA LANDEN TO THE BOARD OF DIRECTORS25.1.2022 18:00:00 CET | Press release

EXTRAORDINARY GENERAL MEETING APPROVES INCREASE OF CONDITIONAL CAPITAL AND SIKA PROPOSES ELECTION OF GORDANA LANDEN TO THE BOARD OF DIRECTORS At an Extraordinary General Meeting, Sika’s shareholders approved the increase of conditional capital. Sika recommends the election of Gordana Landento the Board of Directors at the next Annual General Meeting, to be held on April 12, 2022. On January 25, 2022, an Extraordinary General Meeting of Sika AG was held. Based on Ordinance 3 of the Federal Council on measures to prevent the spread of COVID-19, it was not possible for shareholders to physically attend the Extraordinary General Meeting. Instead, shareholders cast their votes through the independent proxy. The shareholders approved an increase to the existing conditional capital from CHF 155,893.20 (corresponding to 15,589,320 registered shares with a par value of CHF 0.01 each) to CHF 187,893.20 (corresponding to 18,789,320 registered shares with a par value of CHF 0.01 each). Shareholder